Turning Point and Zai Lab Broaden Collaboration
11 janv. 2021 06h45 HE
|
Zai Lab Limited; Turning Point Therapeutics, Inc.
Zai Lab Secures Exclusive Right to Develop and Commercialize TPX-0022, Turning Point’s MET/SRC/CSF1R Inhibitor, in Greater China Turning Point to Receive $25 Million Upfront, with Up to Approximately...
argenx and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater China
06 janv. 2021 16h01 HE
|
Zai Lab Limited; argenx
Collaboration to expand and accelerate global development of efgartigimod; expected to allow argenx to more rapidly advance new potential indications into clinical development each yearZai Lab granted...